الفهرس 
ACUTE MYELOID LEUKEMIAOnly 14 pages are availabe for public view
 |  | from | 156 |  |  |
| | | from | 156 | | |
Abstract
The CD71 (TfR1) is a marker for cell proliferation and activation. All proliferating cells in the hematopoietic system express CD71. Its overexpression has been reported in many neoplasms, including solid tumors and hematological malignancies, denoting its central role in cancer cell pathology. The present study confirmed the probable prognostic value of evaluating CD71 in AML at diagnosis, though larger-scale studies are highly recommended.
The high expression of CD71 was found to be an independent negative prognostic factor and should be added to the routine IPT panel for leukemia diagnosis and risk-stratification. Its potential role for the identification of the MRD, in cases of AML needs further evaluation at multiple stages in post-treatment scenario. Antibodies targeting CD71 have been suggested as an experimental adjuvant antibody-mediated anticancer therapy.
Key words:
CD71: Cluster of differentiation 71. TfR: Transferrin receptor 1. AML: Acute myeloid leukemia. MRD: Minimal residual disease.